*Formerly known as non-alcoholic steatohepatitis (NASH).
The ELF Test
The simple blood test that can assess prognosis of patients with advanced fibrosis due to MASH*
The Enhanced Liver Fibrosis (ELF®) Test is a simple solution to this complex problem with the power to improve outcomes for millions of MASH patients.
Easy to obtain, administer, and interpret, the ELF Test is a routine blood test proven to predict progression to cirrhosis and liver related events in patients with advanced fibrosis (F3 or F4) due to MASH.3 Enabling accessible, effortless testing, the ELF Test simplifies and accelerates the risk stratification of patients with advanced fibrosis due to MASH who may benefit most from potentially life-saving preemptive care; an important first-step in turning the tide against the liver’s silent killer.
The Enhanced Liver Fibrosis (ELF) Test is a noninvasive blood test that quantifies three analytes which directly contribute to liver fibrosis. ELF measurements have proven valuable for assessing the likelihood of disease progression to cirrhosis and liver-related clinical events in patients with advanced fibrosis (F3 or F4) due to MASH.
The widely studied ELF Test can assess based on active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker.
- Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.1,2
- Improve patient care by stratifying MASH patients most at risk of progressing to cirrhosis and LREs.3
- Enhance patient management with a blood test that facilitates more frequent prognostic assessments.
Interpretation of Results
Interpret the ELF score using the following guidelines:
* In the Mid group, the risk of disease progression is similar to the pre-test risk. Pre-test risk refers to the likelihood of disease progression in the overall intended use population without considering the ELF score.
Results should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings.
Assay
Did this information help you?
References
1
Patel P, et al. Hepatol Commun. 2018;2:893-905.
2
Karlas T, et al. PLoS ONE. 2015;10(11):e0141649.
3
Sanyal AJ, et al. Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664. [Epub ahead of print].
The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed.
